JPWO2019157324A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019157324A5 JPWO2019157324A5 JP2020542727A JP2020542727A JPWO2019157324A5 JP WO2019157324 A5 JPWO2019157324 A5 JP WO2019157324A5 JP 2020542727 A JP2020542727 A JP 2020542727A JP 2020542727 A JP2020542727 A JP 2020542727A JP WO2019157324 A5 JPWO2019157324 A5 JP WO2019157324A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- subject
- zfn
- sequence
- aav vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Description
理解を明確にする目的のために図解と実施例によってある程度詳細に開示を提供したが、本開示の趣旨または範囲から逸脱することなく様々な変更や改変を実施することができることが当業者には明らかである。したがって、前述の記載および実施例は、限定として解釈されるべきではない。
特定の実施形態では、例えば以下の項目が提供される。
(項目1)
第1および第2のZFNを含むジンクフィンガーヌクレアーゼ(ZFN)であって、前記第1のZFNが、71557と名付けられたZFNを含み、前記第2のZFNが、71728と名付けられたZFNを含む、ZFN。
(項目2)
必要に応じてAAVベクターに担持される、項目1に記載の第1および第2のZFNをコードする1つまたは複数のポリヌクレオチド。
(項目3)
前記第1のZFNをコードする第1のポリヌクレオチドが、表4に示される配列を含むAAVベクターを含み、前記第2のZFNをコードする第2のポリヌクレオチドが、表5に示される配列を含むAAVベクターを含む、項目2に記載の1つまたは複数のポリヌクレオチド。
(項目4)
前記第1のZFNをコードする前記AAVベクターが、配列番号43に示される配列を含む、項目2または3に記載のAAVベクター。
(項目5)
前記第2のZFNをコードする前記AAVベクターが、配列番号56に示される配列を含む、項目2または3に記載のAAVベクター。
(項目6)
必要に応じて幹細胞もしくは前駆細胞である、項目1に記載の1つもしくは複数のZFN、項目2から3のいずれかに記載の1つもしくは複数のポリヌクレオチド、ならびに/または項目4および5に記載の1つもしくは複数のAAVベクターを含む細胞。
(項目7)
項目1に記載の1つもしくは複数のZFN、項目2から3のいずれかに記載の1つもしくは複数のポリヌクレオチド、項目4および5に記載の1つもしくは複数のAAVベクター、ならびに/または項目6に記載の1つもしくは複数の細胞を含む医薬組成物。
(項目8)
対象において内因性アルブミン遺伝子を切断するための、前記項目のいずれかに記載の、1つもしくは複数のZFN、1つもしくは複数のポリヌクレオチド、1つもしくは複数のAAVベクター、1つもしくは複数の細胞および/または1つもしくは複数の医薬組成物の使用。
(項目9)
前記対象に、必要に応じてAAVベクターに担持されるドナーを投与することをさらに含み、それにより前記ドナーが、前記対象において切断された前記アルブミン遺伝子に組み込まれる、項目8に記載の使用。
(項目10)
対象の細胞において内因性アルブミン遺伝子を切断する方法であって、前記対象に、項目1に記載の1つもしくは複数のZFN、項目2から3のいずれかに記載の1つもしくは複数のポリヌクレオチド、項目4および5に記載の1つもしくは複数のAAVベクター、項目6に記載の1つもしくは複数の細胞ならびに/または項目7に記載の1つもしくは複数の医薬組成物を投与するステップを含む方法。
(項目11)
項目1に記載の1つもしくは複数のZFN、項目2から3のいずれかに記載の1つもしくは複数のポリヌクレオチド、項目4および5に記載の1つもしくは複数のAAVベクター、項目6に記載の1つもしくは複数の細胞ならびに/または項目7に記載の1つもしくは複数の医薬組成物を含むキット。
(項目12)
(a)71557と名付けられた第1のZFNをコードする第1のポリヌクレオチドであって、必要に応じて、表4または配列番号43に示される配列を含むAAVベクターを含む、第1のポリヌクレオチド;
(b)71728と名付けられた第2のZFNをコードする第2のポリヌクレオチドであって、必要に応じて、表5または配列番号56に示される配列を含むAAVベクターを含む、第2のポリヌクレオチド;および
(c)第IX因子(FIX)配列をコードする配列を含むドナーポリヌクレオチド
を含む組成物。
(項目13)
前記ドナーポリヌクレオチドが、表6に示される配列、必要に応じて配列番号59に示される配列を含むAAVベクターである、項目12に記載の組成物。
(項目14)
前記第1の、第2の、およびドナーポリヌクレオチドが、別々のAAVベクターに担持される、項目12または13に記載の組成物。
(項目15)
それを必要とする対象においてFIX導入遺伝子を発現させるための項目12から14のいずれかに記載の組成物の使用であって、前記ZFNが前記対象において内因性アルブミン遺伝子を切断し、前記FIXの配列が切断された前記アルブミン遺伝子に組み込まれ、FIXタンパク質が前記対象において発現されるように、前記組成物が前記対象に投与される、使用。
(項目16)
前記FIXタンパク質の発現の後、前記対象において血友病が処置される、項目15に記載の使用。
(項目17)
それを必要とする対象においてFIXタンパク質を発現させる方法であって、前記FIXタンパク質が細胞中で発現されるように、前記対象に、項目12から14のいずれかに記載の1つまたは複数の組成物を投与するステップを含む方法。
(項目18)
前記対象が、血友病を有し、前記FIXタンパク質の発現が、前記疾患を処置および/または防止する、項目17に記載の方法。
(項目19)
項目12から14のいずれかに記載の1つまたは複数の組成物を含むキット。
(項目20)
(a)71557と名付けられた第1のZFNをコードする第1のポリヌクレオチドであって、必要に応じて、表4または配列番号43に示される配列を含むAAVベクターを含む、第1のポリヌクレオチド;
(b)71728と名付けられた第2のZFNをコードする第2のポリヌクレオチドであって、必要に応じて、表5または配列番号56に示される配列を含むAAVベクターを含む、第2のポリヌクレオチド;および
(c)イズロン酸-2-スルファターゼ(IDS)配列をコードする配列を含むドナーポリヌクレオチド
を含む組成物。
(項目21)
前記ドナーポリヌクレオチドが、表7に示される配列、必要に応じて配列番号65に示される配列を含むAAVベクターである、項目19に記載の組成物。
(項目22)
前記第1の、第2の、およびドナーポリヌクレオチドが、別々のAAVベクターに担持される、項目20または21に記載の組成物。
(項目23)
それを必要とする対象においてIDS導入遺伝子を発現させるための項目20から22のいずれかに記載の組成物の使用であって、前記ZFNが前記対象において内因性アルブミン遺伝子を切断し、前記IDS配列が切断された前記アルブミン遺伝子に組み込まれ、IDSタンパク質が前記対象において発現されるように、前記組成物が前記対象に投与される、使用。
(項目24)
前記IDS配列の発現の後、前記対象においてMPS IIが処置される、項目23に記載の使用。
(項目25)
それを必要とする対象においてIDSタンパク質を発現させる方法であって、前記IDSタンパク質が細胞中で発現されるように、前記対象に、項目20から22のいずれかに記載の1つまたは複数の組成物を投与するステップを含む方法。
(項目26)
前記対象が、MPS II疾患を有し、前記IDSタンパク質の発現が、前記疾患を処置および/または防止する、項目25に記載の方法。
(項目27)
項目20から22のいずれかに記載の1つまたは複数の組成物を含むキット。
(項目28)
(a)71557と名付けられた第1のZFNをコードする第1のポリヌクレオチドであって、必要に応じて、表4または配列番号43に示される配列を含むAAVベクターを含む、第1のポリヌクレオチド;
(b)71728と名付けられた第2のZFNをコードする第2のポリヌクレオチドであって、必要に応じて、表5または配列番号56に示される配列を含むAAVベクターを含む、第2のポリヌクレオチド;および
(c)アルファ-Lイズロニダーゼ(IDUA)配列をコードする配列を含むドナーポリヌクレオチド
を含む組成物。
(項目29)
前記ドナーが、表8に示される配列、必要に応じて配列番号72に示される配列を含む、項目28に記載の組成物。
(項目30)
前記第1の、第2の、およびドナーポリヌクレオチドが、別々のAAVベクターに担持される、項目28または項目29に記載の組成物。
(項目31)
それを必要とする対象においてIDUA導入遺伝子を発現させるための項目28から30のいずれかに記載の組成物の使用であって、前記ZFNが前記対象において内因性アルブミン遺伝子を切断し、前記IDUA配列が切断された前記アルブミン遺伝子に組み込まれ、IDUAタンパク質が前記対象において発現されるように、前記組成物が前記対象に投与される、使用。
(項目32)
前記IDUA配列の発現の後、前記対象においてMPS Iが処置される、項目31に記載の使用。
(項目33)
それを必要とする対象においてIDUAタンパク質を発現させる方法であって、前記IDUAタンパク質が細胞中で発現されるように、前記対象に、項目28から30のいずれかに記載の1つまたは複数の組成物を投与するステップを含む方法。
(項目34)
前記対象が、MPS I疾患を有し、前記IDUAタンパク質の発現が、前記疾患を処置および/または防止する、項目33に記載の方法。
(項目35)
項目28から30のいずれかに記載の1つまたは複数の組成物を含むキット。
The disclosure has been provided in some detail by illustration and examples for the purpose of clarifying understanding, but those skilled in the art will be able to make various changes and modifications without departing from the spirit or scope of this disclosure. it is obvious. Therefore, the above description and examples should not be construed as a limitation.
In certain embodiments, for example, the following items are provided.
(Item 1)
A zinc finger nuclease (ZFN) comprising a first and second ZFN, wherein the first ZFN comprises a ZFN named 71557 and the second ZFN comprises a ZFN named 71728. , ZFN.
(Item 2)
One or more polynucleotides encoding the first and second ZFNs according to item 1, which are optionally carried on an AAV vector.
(Item 3)
The first polynucleotide encoding the first ZFN comprises an AAV vector comprising the sequences shown in Table 4, and the second polynucleotide encoding the second ZFN comprises the sequences shown in Table 5. The polynucleotide according to item 2, which comprises an AAV vector comprising.
(Item 4)
The AAV vector according to item 2 or 3, wherein the AAV vector encoding the first ZFN comprises the sequence shown in SEQ ID NO: 43.
(Item 5)
The AAV vector according to item 2 or 3, wherein the AAV vector encoding the second ZFN comprises the sequence shown in SEQ ID NO: 56.
(Item 6)
The one or more ZFNs according to item 1, one or more polynucleotides according to any of items 2 to 3, and / or items 4 and 5, which are stem cells or progenitor cells as needed. A cell containing one or more AAV vectors of.
(Item 7)
One or more ZFNs according to item 1, one or more polynucleotides according to any one of items 2 to 3, one or more AAV vectors according to items 4 and 5, and / or item 6. A pharmaceutical composition comprising one or more cells according to.
(Item 8)
One or more ZFNs, one or more polynucleotides, one or more AAV vectors, one or more cells according to any of the above items for cleaving an endogenous albumin gene in a subject. And / or the use of one or more pharmaceutical compositions.
(Item 9)
8. The use according to item 8, wherein the subject is optionally administered with a donor carried on an AAV vector, whereby the donor is integrated into the albumin gene cleaved in the subject.
(Item 10)
A method for cleaving an endogenous albumin gene in a target cell, wherein the target is one or more ZFNs according to item 1, or one or more polynucleotides according to any one of items 2 to 3. A method comprising the step of administering one or more AAV vectors according to items 4 and 5, one or more cells according to item 6 and / or one or more pharmaceutical compositions according to item 7.
(Item 11)
Item 1. One or more ZFNs according to item 1, one or more polynucleotides according to any one of items 2 to 3, one or more AAV vectors according to items 4 and 5, item 6. A kit comprising one or more cells and / or one or more pharmaceutical compositions according to item 7.
(Item 12)
(A) A first polynucleotide comprising a first polynucleotide encoding a first ZFN named 71557 and optionally comprising an AAV vector comprising the sequence set forth in Table 4 or SEQ ID NO: 43. nucleotide;
(B) A second polynucleotide encoding a second ZFN named 71728, comprising an AAV vector comprising the sequence set forth in Table 5 or SEQ ID NO: 56, as appropriate. Nucleotides; and
(C) Donor polynucleotide containing a sequence encoding a factor IX (FIX) sequence
Composition containing.
(Item 13)
The composition of item 12, wherein the donor polynucleotide is an AAV vector comprising the sequence shown in Table 6 and optionally the sequence set forth in SEQ ID NO: 59.
(Item 14)
The composition according to item 12 or 13, wherein the first, second, and donor polynucleotides are carried on separate AAV vectors.
(Item 15)
The use of the composition according to any of items 12 to 14 for expressing the FIX transgene in a subject in need thereof, wherein the ZFN cleaves the endogenous albumin gene in the subject and the FIX. Use, wherein the composition is administered to the subject such that the sequence is integrated into the albumin gene and the FIX protein is expressed in the subject.
(Item 16)
The use according to item 15, wherein hemophilia is treated in the subject after expression of the FIX protein.
(Item 17)
A method of expressing a FIX protein in a subject in need thereof, wherein the subject has one or more compositions according to any of items 12-14 such that the FIX protein is expressed in a cell. A method comprising the step of administering a substance.
(Item 18)
17. The method of item 17, wherein the subject has hemophilia and expression of the FIX protein treats and / or prevents the disease.
(Item 19)
A kit comprising one or more compositions according to any of items 12-14.
(Item 20)
(A) A first polynucleotide comprising a first polynucleotide encoding a first ZFN named 71557 and optionally comprising an AAV vector comprising the sequence set forth in Table 4 or SEQ ID NO: 43. nucleotide;
(B) A second polynucleotide encoding a second ZFN named 71728, comprising an AAV vector comprising the sequence set forth in Table 5 or SEQ ID NO: 56, as appropriate. Nucleotides; and
(C) Donor polynucleotide containing a sequence encoding the isulonic acid-2-sulfatase (IDS) sequence
Composition containing.
(Item 21)
19. The composition of item 19, wherein the donor polynucleotide is an AAV vector comprising the sequence shown in Table 7, optionally the sequence set forth in SEQ ID NO: 65.
(Item 22)
The composition according to item 20 or 21, wherein the first, second, and donor polynucleotides are carried on separate AAV vectors.
(Item 23)
The use of the composition according to any of items 20 to 22 for expressing the IDS transgene in a subject in need thereof, wherein the ZFN cleaves the endogenous albumin gene in the subject and the IDS sequence. The composition is administered to the subject such that the albumin gene is cleaved and the IDS protein is expressed in the subject.
(Item 24)
23. The use according to item 23, wherein the MPS II is treated in the subject after expression of the IDS sequence.
(Item 25)
A method of expressing an IDS protein in a subject in need thereof, wherein the subject has one or more compositions according to any of items 20 to 22 such that the IDS protein is expressed in cells. A method comprising the step of administering a substance.
(Item 26)
25. The method of item 25, wherein the subject has an MPS II disease and expression of the IDS protein treats and / or prevents the disease.
(Item 27)
A kit comprising one or more compositions according to any of items 20-22.
(Item 28)
(A) A first polynucleotide comprising a first polynucleotide encoding a first ZFN named 71557 and optionally comprising an AAV vector comprising the sequence set forth in Table 4 or SEQ ID NO: 43. nucleotide;
(B) A second polynucleotide encoding a second ZFN named 71728, comprising an AAV vector comprising the sequence set forth in Table 5 or SEQ ID NO: 56, as appropriate. Nucleotides; and
(C) Donor polynucleotide containing a sequence encoding an alpha-L iduronidase (IDUA) sequence
Composition containing.
(Item 29)
28. The composition of item 28, wherein the donor comprises the sequences shown in Table 8 and optionally the sequences set forth in SEQ ID NO: 72.
(Item 30)
28. The composition of item 28 or item 29, wherein the first, second, and donor polynucleotides are carried on separate AAV vectors.
(Item 31)
The use of the composition according to any of items 28 to 30 for expressing an IDUA-introduced gene in a subject in need thereof, wherein the ZFN cleaves the endogenous albumin gene in the subject and the IDUA sequence. The composition is administered to the subject such that it is integrated into the albumin gene in which it has been cleaved and the IDUA protein is expressed in the subject.
(Item 32)
31. The use according to item 31, wherein the MPS I is treated in the subject after expression of the IDUA sequence.
(Item 33)
A method of expressing an IDUA protein in a subject in need thereof, wherein the subject has one or more compositions according to any of items 28-30 so that the IDUA protein is expressed in cells. A method comprising the step of administering a substance.
(Item 34)
33. The method of item 33, wherein the subject has an MPS I disease and expression of the IDUA protein treats and / or prevents the disease.
(Item 35)
A kit comprising one or more compositions according to any of items 28-30.
Claims (35)
(b)71728と名付けられた第2のZFNをコードする第2のポリヌクレオチドであって、必要に応じて、表5または配列番号56に示される配列を含むAAVベクターを含む、第2のポリヌクレオチド;および
(c)第IX因子(FIX)配列をコードする配列を含むドナーポリヌクレオチド
を含む組成物。 (A) A first polynucleotide comprising a first polynucleotide encoding a first ZFN named 71557 and optionally comprising an AAV vector comprising the sequence set forth in Table 4 or SEQ ID NO: 43. nucleotide;
(B) A second polynucleotide encoding a second ZFN named 71728, comprising an AAV vector comprising the sequence set forth in Table 5 or SEQ ID NO: 56, as appropriate. Nucleotides; and (c) compositions comprising donor polynucleotides comprising a sequence encoding a factor IX (FIX) sequence.
(b)71728と名付けられた第2のZFNをコードする第2のポリヌクレオチドであって、必要に応じて、表5または配列番号56に示される配列を含むAAVベクターを含む、第2のポリヌクレオチド;および
(c)イズロン酸-2-スルファターゼ(IDS)配列をコードする配列を含むドナーポリヌクレオチド
を含む組成物。 (A) A first polynucleotide comprising a first polynucleotide encoding a first ZFN named 71557 and optionally comprising an AAV vector comprising the sequence set forth in Table 4 or SEQ ID NO: 43. nucleotide;
(B) A second polynucleotide encoding a second ZFN named 71728, comprising an AAV vector comprising the sequence set forth in Table 5 or SEQ ID NO: 56, as appropriate. Nucleotides; and (c) A composition comprising a donor polynucleotide comprising a sequence encoding an isulonic acid-2-sulfatase (IDS) sequence.
(b)71728と名付けられた第2のZFNをコードする第2のポリヌクレオチドであって、必要に応じて、表5または配列番号56に示される配列を含むAAVベクターを含む、第2のポリヌクレオチド;および
(c)アルファ-Lイズロニダーゼ(IDUA)配列をコードする配列を含むドナーポリヌクレオチド
を含む組成物。 (A) A first polynucleotide comprising a first polynucleotide encoding a first ZFN named 71557 and optionally comprising an AAV vector comprising the sequence set forth in Table 4 or SEQ ID NO: 43. nucleotide;
(B) A second polynucleotide encoding a second ZFN named 71728, comprising an AAV vector comprising the sequence set forth in Table 5 or SEQ ID NO: 56, as appropriate. Nucleotides; and (c) compositions comprising donor polynucleotides comprising a sequence encoding an alpha-L islonidase (IDUA) sequence.
A kit comprising one or more compositions according to any one of claims 28-30.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023076356A JP2023090871A (en) | 2018-02-08 | 2023-05-02 | Engineered target-specific nucleases |
Applications Claiming Priority (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862628016P | 2018-02-08 | 2018-02-08 | |
US62/628,016 | 2018-02-08 | ||
US201862728226P | 2018-09-07 | 2018-09-07 | |
US62/728,226 | 2018-09-07 | ||
US201862758786P | 2018-11-12 | 2018-11-12 | |
US62/758,786 | 2018-11-12 | ||
US201962795937P | 2019-01-23 | 2019-01-23 | |
US62/795,937 | 2019-01-23 | ||
US201962802092P | 2019-02-06 | 2019-02-06 | |
US62/802,092 | 2019-02-06 | ||
PCT/US2019/017273 WO2019157324A1 (en) | 2018-02-08 | 2019-02-08 | Engineered target specific nucleases |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023076356A Division JP2023090871A (en) | 2018-02-08 | 2023-05-02 | Engineered target-specific nucleases |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2021513338A JP2021513338A (en) | 2021-05-27 |
JPWO2019157324A5 true JPWO2019157324A5 (en) | 2022-02-07 |
JP7275152B2 JP7275152B2 (en) | 2023-05-17 |
Family
ID=67476462
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020542727A Active JP7275152B2 (en) | 2018-02-08 | 2019-02-08 | Engineered target-specific nucleases |
JP2023076356A Pending JP2023090871A (en) | 2018-02-08 | 2023-05-02 | Engineered target-specific nucleases |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023076356A Pending JP2023090871A (en) | 2018-02-08 | 2023-05-02 | Engineered target-specific nucleases |
Country Status (13)
Country | Link |
---|---|
US (2) | US11401512B2 (en) |
EP (1) | EP3749350A4 (en) |
JP (2) | JP7275152B2 (en) |
KR (1) | KR20200118468A (en) |
CN (1) | CN111954540A (en) |
AU (1) | AU2019218118A1 (en) |
BR (1) | BR112020015488A2 (en) |
CA (1) | CA3089587A1 (en) |
IL (1) | IL276490A (en) |
MX (1) | MX2020008272A (en) |
RU (1) | RU2020129448A (en) |
SG (1) | SG11202007440YA (en) |
WO (1) | WO2019157324A1 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110022904B (en) | 2016-10-20 | 2024-04-19 | 桑格摩生物治疗股份有限公司 | Methods and compositions for treating brile disease |
US11512287B2 (en) * | 2017-06-16 | 2022-11-29 | Sangamo Therapeutics, Inc. | Targeted disruption of T cell and/or HLA receptors |
US20200063160A1 (en) | 2018-08-07 | 2020-02-27 | Sangamo Therapeutics, Inc. | Method for the treatment of mucopolysaccharidosis type ii |
SG11202107325TA (en) * | 2019-01-04 | 2021-08-30 | Sangamo Therapeutics Inc | Methods and compositions for the treatment of fabry disease |
CN112805026A (en) | 2019-02-06 | 2021-05-14 | 桑格摩生物治疗股份有限公司 | Methods for treating mucopolysaccharidosis type I |
EP4051322A1 (en) | 2019-11-01 | 2022-09-07 | Sangamo Therapeutics, Inc. | Compositions and methods for genome engineering |
US20230323390A1 (en) * | 2020-06-11 | 2023-10-12 | Sangamo Therapeutics, Inc. | Methods and compositions for expressing phenylalanine hydroxylase |
CN113293165B (en) * | 2021-06-21 | 2022-11-15 | 军事科学院军事医学研究院环境医学与作业医学研究所 | HEV specific crRNA based on CRISPR-Cas12a technology, detection kit and application thereof |
WO2023039598A1 (en) * | 2021-09-13 | 2023-03-16 | Life Technologies Corporation | Gene editing tools |
Family Cites Families (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5487994A (en) | 1992-04-03 | 1996-01-30 | The Johns Hopkins University | Insertion and deletion mutants of FokI restriction endonuclease |
US5436150A (en) | 1992-04-03 | 1995-07-25 | The Johns Hopkins University | Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease |
US5356802A (en) | 1992-04-03 | 1994-10-18 | The Johns Hopkins University | Functional domains in flavobacterium okeanokoites (FokI) restriction endonuclease |
US6140466A (en) | 1994-01-18 | 2000-10-31 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
US6242568B1 (en) | 1994-01-18 | 2001-06-05 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
JP4012243B2 (en) | 1994-01-18 | 2007-11-21 | ザ スクリップス リサーチ インスティチュート | Zinc finger protein derivatives and methods therefor |
AU698152B2 (en) | 1994-08-20 | 1998-10-22 | Gendaq Limited | Improvements in or relating to binding proteins for recognition of DNA |
GB9824544D0 (en) | 1998-11-09 | 1999-01-06 | Medical Res Council | Screening system |
US5789538A (en) | 1995-02-03 | 1998-08-04 | Massachusetts Institute Of Technology | Zinc finger proteins with high affinity new DNA binding specificities |
US5925523A (en) | 1996-08-23 | 1999-07-20 | President & Fellows Of Harvard College | Intraction trap assay, reagents and uses thereof |
GB9703369D0 (en) | 1997-02-18 | 1997-04-09 | Lindqvist Bjorn H | Process |
GB2338237B (en) | 1997-02-18 | 2001-02-28 | Actinova Ltd | In vitro peptide or protein expression library |
GB9710809D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
GB9710807D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
US6410248B1 (en) | 1998-01-30 | 2002-06-25 | Massachusetts Institute Of Technology | General strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites |
CA2321938C (en) | 1998-03-02 | 2009-11-24 | Massachusetts Institute Of Technology | Poly zinc finger proteins with improved linkers |
US6140081A (en) | 1998-10-16 | 2000-10-31 | The Scripps Research Institute | Zinc finger binding domains for GNN |
US7070934B2 (en) | 1999-01-12 | 2006-07-04 | Sangamo Biosciences, Inc. | Ligand-controlled regulation of endogenous gene expression |
US7013219B2 (en) | 1999-01-12 | 2006-03-14 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
US6599692B1 (en) | 1999-09-14 | 2003-07-29 | Sangamo Bioscience, Inc. | Functional genomics using zinc finger proteins |
US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
US6453242B1 (en) | 1999-01-12 | 2002-09-17 | Sangamo Biosciences, Inc. | Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites |
US6794136B1 (en) | 2000-11-20 | 2004-09-21 | Sangamo Biosciences, Inc. | Iterative optimization in the design of binding proteins |
US7030215B2 (en) | 1999-03-24 | 2006-04-18 | Sangamo Biosciences, Inc. | Position dependent recognition of GNN nucleotide triplets by zinc fingers |
US6379903B1 (en) | 1999-10-08 | 2002-04-30 | Sigma-Aldrich Co. | Purification of recombinant proteins fused to multiple epitopes |
IL150069A0 (en) | 1999-12-06 | 2002-12-01 | Sangamo Biosciences Inc | Methods of using randomized libraries of zinc finger proteins for the identification of gene function |
US6689558B2 (en) | 2000-02-08 | 2004-02-10 | Sangamo Biosciences, Inc. | Cells for drug discovery |
US20020061512A1 (en) | 2000-02-18 | 2002-05-23 | Kim Jin-Soo | Zinc finger domains and methods of identifying same |
WO2001088197A2 (en) | 2000-05-16 | 2001-11-22 | Massachusetts Institute Of Technology | Methods and compositions for interaction trap assays |
JP2002060786A (en) | 2000-08-23 | 2002-02-26 | Kao Corp | Germicidal stainproofing agent for hard surface |
US7419829B2 (en) | 2000-10-06 | 2008-09-02 | Oxford Biomedica (Uk) Limited | Vector system |
AU2002217929A1 (en) | 2000-11-28 | 2002-06-11 | Sangamo Biosciences, Inc. | Modulation of gene expression using insulator binding proteins |
US7067317B2 (en) | 2000-12-07 | 2006-06-27 | Sangamo Biosciences, Inc. | Regulation of angiogenesis with zinc finger proteins |
US7273923B2 (en) | 2001-01-22 | 2007-09-25 | Sangamo Biosciences, Inc. | Zinc finger proteins for DNA binding and gene regulation in plants |
GB0108491D0 (en) | 2001-04-04 | 2001-05-23 | Gendaq Ltd | Engineering zinc fingers |
WO2003016496A2 (en) | 2001-08-20 | 2003-02-27 | The Scripps Research Institute | Zinc finger binding domains for cnn |
US7262054B2 (en) | 2002-01-22 | 2007-08-28 | Sangamo Biosciences, Inc. | Zinc finger proteins for DNA binding and gene regulation in plants |
CA2474486C (en) | 2002-01-23 | 2013-05-14 | The University Of Utah Research Foundation | Targeted chromosomal mutagenesis using zinc finger nucleases |
AU2003218382B2 (en) | 2002-03-21 | 2007-12-13 | Sangamo Therapeutics, Inc. | Methods and compositions for using zinc finger endonucleases to enhance homologous recombination |
US7361635B2 (en) | 2002-08-29 | 2008-04-22 | Sangamo Biosciences, Inc. | Simultaneous modulation of multiple genes |
AU2003298574B2 (en) | 2002-09-05 | 2008-04-24 | California Institute Of Technology | Use of chimeric nucleases to stimulate gene targeting |
US7888121B2 (en) | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
US8409861B2 (en) | 2003-08-08 | 2013-04-02 | Sangamo Biosciences, Inc. | Targeted deletion of cellular DNA sequences |
US7972854B2 (en) | 2004-02-05 | 2011-07-05 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
JP2008506359A (en) | 2004-04-08 | 2008-03-06 | サンガモ バイオサイエンシズ インコーポレイテッド | Treatment of neuropathic pain with zinc finger protein |
CA2561714A1 (en) | 2004-04-08 | 2005-10-27 | Sangamo Biosciences, Inc. | Methods and compositions for treating neuropathic and neurodegenerative conditions |
US20060063231A1 (en) | 2004-09-16 | 2006-03-23 | Sangamo Biosciences, Inc. | Compositions and methods for protein production |
JP2009502170A (en) | 2005-07-26 | 2009-01-29 | サンガモ バイオサイエンシズ インコーポレイテッド | Targeted integration and expression of foreign nucleic acid sequences |
JP5266210B2 (en) | 2006-05-25 | 2013-08-21 | サンガモ バイオサイエンシズ インコーポレイテッド | Modified cleavage half-domain |
EP2447279B1 (en) | 2006-05-25 | 2014-04-09 | Sangamo BioSciences, Inc. | Methods and compositions for gene inactivation |
ATE489465T1 (en) | 2007-04-26 | 2010-12-15 | Sangamo Biosciences Inc | TARGETED INTEGRATION INTO THE PPP1R12C POSITION |
US8563314B2 (en) | 2007-09-27 | 2013-10-22 | Sangamo Biosciences, Inc. | Methods and compositions for modulating PD1 |
ES2459880T3 (en) | 2008-04-14 | 2014-05-12 | Sangamo Biosciences, Inc. | Linear donor constructions for targeted integration |
US8597912B2 (en) | 2008-06-10 | 2013-12-03 | Sangamo Biosciences, Inc. | Methods and compositions for generation of Bax-and Bak-deficient cell lines |
KR20160015400A (en) | 2008-08-22 | 2016-02-12 | 상가모 바이오사이언스 인코포레이티드 | Methods and compositions for targeted single-stranded cleavage and targeted integration |
WO2010065123A1 (en) | 2008-12-04 | 2010-06-10 | Sangamo Biosciences, Inc. | Genome editing in rats using zinc-finger nucleases |
EP2206723A1 (en) | 2009-01-12 | 2010-07-14 | Bonas, Ulla | Modular DNA-binding domains |
US8956828B2 (en) | 2009-11-10 | 2015-02-17 | Sangamo Biosciences, Inc. | Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases |
WO2011097036A1 (en) | 2010-02-08 | 2011-08-11 | Sangamo Biosciences, Inc. | Engineered cleavage half-domains |
EP2534163B1 (en) | 2010-02-09 | 2015-11-04 | Sangamo BioSciences, Inc. | Targeted genomic modification with partially single-stranded donor molecules |
JP5952263B2 (en) | 2010-04-26 | 2016-07-13 | サンガモ バイオサイエンシーズ, インコーポレイテッド | Genome editing of the ROSA locus using zinc finger nuclease |
WO2011139349A1 (en) | 2010-05-03 | 2011-11-10 | Sangamo Biosciences, Inc. | Compositions for linking zinc finger modules |
CN103025344B (en) | 2010-05-17 | 2016-06-29 | 桑格摩生物科学股份有限公司 | Novel DNA-associated proteins and application thereof |
JP6050230B2 (en) | 2010-07-21 | 2016-12-21 | サンガモ バイオサイエンシーズ, インコーポレイテッド | Methods and compositions for modification of HLA loci |
CN102358902B (en) * | 2011-04-02 | 2013-01-02 | 西南大学 | Silkworm fibroin heavy-chain gene mutation sequence and mutation method and application |
SG10201811736QA (en) | 2011-09-21 | 2019-02-27 | Sangamo Therapeutics Inc | Methods and compositions for regulation of transgene expression |
WO2013063315A2 (en) | 2011-10-27 | 2013-05-02 | Sangamo Biosciences, Inc. | Methods and compositions for modification of the hprt locus |
JP6144691B2 (en) | 2011-11-16 | 2017-06-07 | サンガモ セラピューティクス, インコーポレイテッド | Modified DNA binding proteins and uses thereof |
EP3444342B1 (en) | 2012-07-11 | 2020-05-27 | Sangamo Therapeutics, Inc. | Methods and compositions for the treatment of lysosomal storage diseases |
KR102474010B1 (en) * | 2012-08-29 | 2022-12-02 | 상가모 테라퓨틱스, 인코포레이티드 | Methods and compositions for treatment of a genetic condition |
AU2013355327A1 (en) | 2012-12-05 | 2015-06-11 | Sangamo Therapeutics, Inc. | Methods and compositions for regulation of metabolic disorders |
ES2738641T3 (en) * | 2012-12-18 | 2020-01-24 | Novartis Ag | Production of therapeutic proteins in genetically modified mammalian cells |
EP3730615A3 (en) | 2013-05-15 | 2020-12-09 | Sangamo Therapeutics, Inc. | Methods and compositions for treatment of a genetic condition |
JP6588438B2 (en) | 2013-08-28 | 2019-10-09 | サンガモ セラピューティクス, インコーポレイテッド | Composition for linking a DNA binding domain and a cleavage domain |
JP6535684B2 (en) * | 2013-12-09 | 2019-06-26 | サンガモ セラピューティクス, インコーポレイテッド | Methods and compositions for genome manipulation |
US10179918B2 (en) | 2015-05-07 | 2019-01-15 | Sangamo Therapeutics, Inc. | Methods and compositions for increasing transgene activity |
WO2017074526A1 (en) | 2015-10-28 | 2017-05-04 | Sangamo Biosciences, Inc. | Liver-specific constructs, factor viii expression cassettes and methods of use thereof |
IL297018A (en) | 2015-12-18 | 2022-12-01 | Sangamo Therapeutics Inc | Targeted disruption of the mhc cell receptor |
SG11201805680SA (en) * | 2016-01-15 | 2018-07-30 | Sangamo Therapeutics Inc | Methods and compositions for the treatment of neurologic disease |
IL264639B2 (en) | 2016-08-24 | 2024-01-01 | Sangamo Therapeutics Inc | Regulation of globulin gene expression using engineered zinc finger nucleases |
BR112019003327A2 (en) | 2016-08-24 | 2019-07-02 | Sangamo Therapeutics Inc | specific target engineered nucleases |
US20180185516A1 (en) | 2016-12-09 | 2018-07-05 | Sangamo Therapeutics, Inc. | Delivery of target specific nucleases |
US20200063160A1 (en) * | 2018-08-07 | 2020-02-27 | Sangamo Therapeutics, Inc. | Method for the treatment of mucopolysaccharidosis type ii |
-
2019
- 2019-02-08 AU AU2019218118A patent/AU2019218118A1/en active Pending
- 2019-02-08 MX MX2020008272A patent/MX2020008272A/en unknown
- 2019-02-08 CA CA3089587A patent/CA3089587A1/en active Pending
- 2019-02-08 RU RU2020129448A patent/RU2020129448A/en unknown
- 2019-02-08 KR KR1020207025636A patent/KR20200118468A/en unknown
- 2019-02-08 EP EP19751240.3A patent/EP3749350A4/en active Pending
- 2019-02-08 CN CN201980024453.9A patent/CN111954540A/en active Pending
- 2019-02-08 BR BR112020015488-1A patent/BR112020015488A2/en unknown
- 2019-02-08 JP JP2020542727A patent/JP7275152B2/en active Active
- 2019-02-08 WO PCT/US2019/017273 patent/WO2019157324A1/en active Application Filing
- 2019-02-08 SG SG11202007440YA patent/SG11202007440YA/en unknown
- 2019-02-08 US US16/271,250 patent/US11401512B2/en active Active
-
2020
- 2020-08-04 IL IL276490A patent/IL276490A/en unknown
-
2022
- 2022-06-23 US US17/848,330 patent/US20230067653A1/en active Pending
-
2023
- 2023-05-02 JP JP2023076356A patent/JP2023090871A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2020129448A (en) | DESIGNED TARGET-SPECIFIC NUCLEASE | |
Hadebe et al. | The SAFE pathway for cardioprotection: is this a promising target? | |
US20230118337A1 (en) | Compositions and methods for the treatment of hemoglobinopathies | |
US11479775B2 (en) | RNA targeting of mutations via suppressor tRNAs and deaminases | |
Semenza | Hypoxia-inducible factor 1 and cardiovascular disease | |
JP2017504354A5 (en) | ||
JP2017500061A5 (en) | ||
JP2020500162A5 (en) | ||
Jackson et al. | Therapeutic manipulation of mtDNA heteroplasmy: a shifting perspective | |
JP2018531614A5 (en) | ||
Fardilha et al. | Protein phosphatase 1 complexes modulate sperm motility and present novel targets for male infertility | |
JP2015533786A5 (en) | ||
JP2016539627A5 (en) | ||
JP2019500043A5 (en) | ||
JPWO2019157324A5 (en) | ||
Bueren et al. | Advances in the gene therapy of monogenic blood cell diseases | |
JP2013530689A5 (en) | ||
McNally et al. | Cloning and expression of the adenosine kinase gene from rat and human tissues | |
Choudhary et al. | Telomere and telomerase in stem cells: relevance in ageing and disease | |
Kimura et al. | Redox signaling in cardiac renewal | |
GB2560250A (en) | ATP-Binding cassette family coding polyribonucleotides and formulations thereof | |
CN1354671A (en) | Method for inhibition of phospholamban activity for treatment of cardiac disease and heart failure | |
Kyriakopoulou et al. | Gene editing innovations and their applications in cardiomyopathy research | |
Uda et al. | Origin and properties of cytoplasmic and mitochondrial isoforms of taurocyamine kinase | |
Tatsumi et al. | 2′, 5′-oligoadenylate synthetase gene in chicken: gene structure, distribution of alleles and their expression |